News summarySEC EDGARNov 4, 2026, 12:00 PM
Summit Therapeutics 8-K (2.02, 5.03, 5.07, 9.01): reported results of operations
Summit Therapeutics reported third-quarter and nine-month 2026 results and clinical progress, including a $2 billion post-quarter AstraZeneca equity investment, $629.8 million in quarter-end cash and investments, and statistically significant overall-survival benefits in two Akeso Phase III studies.